HealthInvestor Asia Summit 2018
Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Analysis: A new framework for 3D printed medical devices in Australia

The rise of 3D printing technology in medicine and healthcare is challenging existing regulatory frameworks as higher risk 3D printed medical devices are developed. Tracy Lu, senior associate for Allens in Sydney, explains that Australia is at the forefront of dealing with this regulatory reassessment.

The definition of a custom-made device – under the Therapeutic Goods Regulations – is currently sufficiently broad to capture a range of medical devices, from those that are adapted from a standard template to suit a patient’s anatomy to devices which are truly one-off.

Custom-made devices are currently subject to limited conformity assessment procedures and are exempt from premarket assessment, although they are not exempt from post-market monitoring.

The existing regulatory regime for custom-made devices was developed when the risk associated with such devices was low. With the advent of medical 3D printing technology, however, more and more higher risk devices (which would otherwise attract higher risk classifications and stringent premarket oversight) are being released to the market.

In response to this change in environment, the TGA has put forward five proposals in a recent consultation paper.

First, a new umbrella term “personalised medical devices” is proposed, which will include the subcategories “custom made”, “customised” and “patient-specific”. Custom made devices would be limited to those intended for the sole use of a particular patient and for which there is no commercially available alternative. This definition also excludes mass produced devices adapted to suit specific requirements of any professional user and patient-specific devices.

Customised devices would refer to devices supplied by a manufacturer with a specific intended purpose that must be adapted or assembled, in accordance with the manufacturer’s validated instructions, to suit an individual patient. Patient-specific devices would refer to devices based on a standard template model that is matched to a patient’s anatomy, or by using the full anatomic features from patient imaging.

At a recent 3D printing in Medicine and Healthcare industry event hosted by Allens, a representative of the TGA noted that the changes to the definitions are the most significant changes in this consultation paper. A new vocabulary would allow all the relevant stakeholders to have meaningful conversations regarding 3D printing in the context of medical device regulations.

Second, given the proposed changes to custom-made devices, the more limited conformity assessment procedures would now apply to a narrower subset of devices and the TGA would also have the power to enter and inspect manufacturing sites. Next, for customised devices, the TGA proposes that a manufacturer’s liability would be limited only to adaptations which are carried out in accordance with the manufacturer’s validated instructions. Further, the TGA recognises that some healthcare providers may have in-house 3D printing capability which allows them to produce devices which would fall under the current definition of custom made devices and the new proposed definition of patient-specific devices. This means that the exemptions for custom made devices would no longer apply. Therefore, where the patient-specific device is of a lower risk classification, TGA proposes to exempt such providers from regulation as a manufacturer.

Fourth, devices that are intended by the manufacturer to be used to record diagnostic images (for example 3D scanners) would have the same classification as X-rays. And finally, medical devices incorporating materials of human origin would be regulated as medical devices rather than biologicals (for which different regulatory requirements apply), so that there is consistency of approach across medical devices.

It is positive to see the Australian regulator take a proactive role in addressing the regulatory challenges posed by medical 3D printing. TGA in fact chairs the issue of personalised medical devices for the International Medical Device Regulators Forum, which aims to harmonise regulatory approaches across a number of jurisdictions. The TGA’s recent proposals, however, do not cover technical considerations for designing, manufacturing and testing such devices – it is also important to develop adequate quality controls over those aspects to ensure the safety and wellbeing of patients.

Posted on: 29/11/2017 UTC+08:00


News

Shares in orthopaedic specialists Asian Healthcare Specialists (AHS) shot up 52% at the open on their Catalist debut today.
Private equity firm Permira’s A$690 million (US$536 million) five-year leveraged buyout loan to help it acquire EQT’s stake in I-MED Radiology Network, Australia’s largest radiology company, has been flexed down.
Joanne Hannah has resigned as chief executive of Total Face Group, the first medical aesthetics company to list on the ASX, effective 1 May.
Lianluo Smart, which develops medical devices and wearable sleep respiratory products, has signed a strategic cooperation agreement with Meinian Onehealth Healthcare, the second largest healthcare provider in China.
After a choppy day of trading that saw shares in HKE Holdings, a Singapore-based contractor specialising in the medical and healthcare sectors, rise as much as 10%, they closed up 1.82% on their debut yesterday.
Summerset Group, New Zealand’s third-largest listed retirement village operator, has purchased land to build a retirement village in the suburb of Te Awa. The 9-ha property will be Summerset’s fourth in Hawke’s Bay. It already has villages in Havelock North, Hastings and Taradale.
Metlifecare, New Zealand’s second-largest listed retirement village operator, has said that its purchase of a 5.3 hectare waterfront site at Orion Point in Hobsonville, West Auckland, is now unconditional. The deal was announced at the end of October last year.
Hong Kong care home operator Pine Care Group has signed a management agreement with Zhejiang Yada Real Estate to operate and manage the Wuzhen Graceland Day Care Centre in Wuzhen, Zhejiang. Financial terms have not been disclosed.



Analysis

In Vietnam, population and GDP growth have encouraged the country to think beyond technology in providing more health for more people.
Focused initiatives drive down medical inflation by more than 50 percentage points, according to a new report from Aon Asia Healthcare.
The Japanese healthcare system is a shining example of strength and resilience. At an average lifespan of 84 years, the Japanese society is not only the healthiest but also the "oldest" in the world. However, the challenges presented by an ageing population pose serious threats to the sustainability of the Japanese health system.
Susann Roth, senior social development specialist, Asian Development Bank, explains how investing in energy makes people healthier.
CFO Luke Chen’s reticence on the Q3 earnings call on Friday now makes sense. Jack Ma’s Yunfeng Capital and Alibaba Investment will buy out iKang Healthcare Group, China’s largest private preventive healthcare services provider, for around US$1.4 billion.
Following news that Malaysian sovereign wealth fund Khazanah Nasional will acquire Prince Court Medical Centre (PCMC) from Petronas, IHH Healthcare, Asia’s largest healthcare company, has signed an agreement with Khazanah to look after the day-to-day running of the medical centre.
Malaysian-based primary healthcare provider Qualitas Medical Group is due to push the button on its S$150 million (US$114 million) IPO in Singapore next week. It will be the first mainboard healthcare listing since IHH Healthcare floated in Kuala Lumpur and Singapore in July 2012.
Sumit Sharma, head of health & life sciences, Asia Pacific, at Oliver Wyman, and Matt Zafra, engagement manager, health & life sciences, Oliver Wyman, look at the four themes that are going to dominate healthcare this year.
my images

Podcasts

Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices